Furthermore, roblitinib, a selective inhibitor of FGFR4, was found to be potently effective against anti-HER2-resistant breast cancer [15]. These studies greatly support the design of future clinical investigations in the treatment of anti-HER2-resistant breast cancer. Here, FGFR4 is linked to breast carcinoma.